Drugs / SENS-501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06370351 | Jun 2024 → Jul 2027 expected | autosomal recessive nonsyndromic hearing loss 9, disorder of ear, prelingual non-syndromic genetic hearing loss, sensorineural hearing loss disorder | Sensorion | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SENS-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06370351 ↗ |
| Route | Other | “Unilateral Intracochlear Injection of SENS-501 Using an Injection System” NCT06370351 ↗ |